Neurogene collaborates with patients and their families to ACCOMPLISH OUR SHARED MISSION

We attend family meetings to engage families in our process, create connections, and get to know their stories.

We are on a mission to develop life-changing medicines for patients and families affected by rare neurological disorders, and we believe the best approach to addressing the urgent unmet needs of these families is a collaborative one.

In partnership with advocacy organizations, family foundations, patients, and disease experts around the world, we are working to determine and address the root cause of diseases such as aspartylglucosaminuria (AGU), Charcot-Marie-Tooth Type 4J (CMT4J), and two forms of Batten disease, CLN7 and CLN5. Our patient engagement team develops and nurtures relationships with families to understand their perspectives and unique needs, as well as find opportunities to bring solutions and resources to support their disease journeys.

Our COMMUNITY

We engage families in focus groups to gain insight on the impact of disease symptoms, the burden of disease and to better understand living with the disease.

We share updates and projects we are working on to help educate the rare disease community. Working with patient families enables us to gain insight from the experts who live with the disease every day. This information is often incorporated into the development of educational materials.

We include patient families in discussions to better understand living with the disease so that natural history studies and clinical trials are developed to reach impactful outcomes.

Our FOCUS and IMPACT

Neurogene’s commitment to monogenic neurological disease areas goes beyond the science; we want to raise awareness and connect the community to resources and support that can guide their journey.

Aspartylglucosaminuria (AGU)

Aspartylglucosaminuria (AGU) is a rare, neurodegenerative lysosomal storage disorder (LSD). AGU primarily affects the brain and spinal cord. Early symptoms of AGU usually appear by the age of 12 to 15 months and include developmental delay, specifically lack of speech and clumsy walking, and chronic ear infections. New signs and symptoms of the disorder develop and progress over time.

LSDs are a group of inherited metabolic diseases caused by genetic mutations. Each mutation causes a deficiency or absence of a critical enzyme. The lack of enzyme leads to the build-up of toxic chemicals that affect many organs in the body. AGU is caused by a variant in the AGA gene that causes deficient activity in the aspartylglucosaminidase (AGA) enzyme.

AGU affects both males and females as well as people of all ethnic groups. There are about 200 to 300 known AGU patients worldwide. People with AGU have been diagnosed in Finland, the United States, Japan, Italy, Canada, and other Nordic countries.

We are proud to offer LivingAGU.com, a community-focused resource for patients and families. Discover helpful resources and support for AGU to guide you along your journey.

See how we are REIMAGINING THE FUTURE

Visit our product pipeline to learn more about Neurogene’s pursuit of gene therapy candidates for our disease areas of focus.

Clinical STUDIES

In order to better understand the course of each disease that we are working to address, Neurogene is conducting clinical studies.

There are two types of studies: non-interventional or interventional.

Natural history studies are non-interventional and, as such, there are no therapies involved; they can be prospective, which tracks the course of disease over time, or retrospective, where researchers review and examine factors by looking back at past medical events.

To find the three natural history studies that Neurogene is currently conducting – for AGU, CMT4J, and CLN7 and CLN5, visit ClinicalTrials.gov.

A Natural History Study of Aspartylglucosaminuria (AGU)

A Natural History Study of Charcot-Marie-Tooth 4J (CMT4J)

A Natural History Study of Late Infantile Variant CLN7 and CLN5 Disease